ArticleMicrobiologyOpen2019
Bioactivities and genome insights of a thermotolerant antibiotics-producing Streptomyces sp. TM32 reveal its potentials for novel drug discovery.
Article in MicrobiologyOpen, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- GC-MS Profiling and In Silico Pathway Mapping of Brevibacterium casei VRK 1 Metabolites for exploring Anti-inflammatory and Antioxidant Activities.Applied biochemistry and biotechnology · 2025Article
- Discovery of 15-deoxynaphthomycins activating the antioxidant NRF2-ARE pathway from Streptomyces sp. N50 via genome mining, global regulator introduction, and molecular networking.Microbial cell factories · 2025Article
- Comparative analysis of rhizosphere microbial communities and secondary metabolites in cultivatedFrontiers in plant science · 2025Article
- Insights into the mechanisms of microbiome and metabolome changes mediated by understory interplanting mode inFrontiers in microbiology · 2023Article
- Complete genome sequencing andFrontiers in microbiology · 2022Article
- Article
- Insights into the mechanism of the effects of rhizosphere microorganisms on the quality of authentic Angelica sinensis under different soil microenvironments.BMC plant biology · 2021Article
- Genomic and Metabolomic Investigation of a Rhizosphere IsolateMolecules (Basel, Switzerland) · 2021Article
- Whole genome sequencing ofBiotechnology reports (Amsterdam, Netherlands) · 2021Article
- Review
- Genome Mining Revealed a High Biosynthetic Potential for AntifungalInternational journal of molecular sciences · 2020Article
- Article
- Bioactivities and genome insights of a thermotolerant antibiotics-producing Streptomyces sp. TM32 reveal its potentials for novel drug discovery.MicrobiologyOpen · 2019Article
- Antimicrobial resistance: A multifaceted problem with multipronged solutions.MicrobiologyOpen · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A way to defeat antimicrobial resistance (AMR) crisis is to supply novel drugs to the pharmaceutical industry. This effort leads to a global call for seeking the beneficial microbes from underexplored habitats. To support this call, we isolated Streptomyces sp. TM32 from the rhizosphere soil of a medicinal plant, turmeric (Curcuma longa L.). TM32 exhibited strong antimicrobial activities against both human and plant pathogens, including an AMR pathogen, Staphylococcus haemolyticus MR-CoNS. Surprisingly, such antimicrobial results of TM32's autoclaved crude extract remained the same. Based on the genome data analysis, TM32 belongs to the same genomic species with Streptomyces sioyaensis DSM 40032
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.